Top 8 blockbuster biologicals 2013

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Top 8 blockbuster biologicals 2013

Biosimilares/General | Posted 06/06/2014 0 Post your comment

The top three best-selling drugs during 2013 were biologicals. All three best-sellers are indicated for the treatment of arthritis, and include Abbott’s Humira (adalimumab), Merck’s Remicade (infliximab) and Roche’s Rituxan/MabThera (rituximab).

In fact, seven of the top eight best-selling drugs for 2013 were biologicals and eight of the top 15 were also biologicals, see Table 1.

All the biologicals on the 2013 list had increased sales compared with 2012. The biggest sales increases were for Sanofi’s diabetes treatment Lantus (insulin glargine) and Abbott’s arthritis treatment Humira, with sales increases of 15.2% and 15%, respectively, compared to 2012.

Biologicals to treat cancer also represented three of the top eight best-sellers, and included Rituxan (Non-Hodgkin’s lymphoma), Herceptin (breast cancer) and Avastin (colorectal, lung and kidney cancer).

Six of the top eight blockbuster biologicals are antibodies, the top selling therapeutic proteins are insulin glargine and pegfilgrastim. The anti-TNF antibody Humira (adalimumab) is the top selling single brand of a recombinant biological with 2013 sales of US$10.7 billion, up from US$9.5 in 2012 [1], see Table 1.

Table 1: Top 8 blockbuster biologicals 2013

Brand name	Active ingredient	Type	Class	Treatment	Company	2013 global sales (US$ billion)	Patent expiry EU/US [2]
Humira	adalimumab	Antibody	TNF inhibitor	Arthritis	Abbott/Eisai	10.7	Apr 2018/ Dec 2016
Remicade	infliximab	Antibody	TNF inhibitor	Arthritis	Merck/Mitsubishi	8.9	Aug 2014/ Sep 2018
Rituxan/MabThera	rituximab	Antibody	Anti-CD20	Arthritis, NHL	Roche/Biogen-Idec	8.6	Nov 2013/ Dec 2018
Enbrel	etanercept	Antibody	TNF inhibitor	Arthritis	Amgen/Pfizer/Takeda	8.3	Feb 2015/ Nov 2028
Lantus	insulin glargine	Protein	Insulin receptor	Diabetes	Sanofi	7.8	2014/2014
Avastin	bevacizumab	Antibody	Anti-angiogenesis	Cancer	Roche	7.0	Jan 2022/ Jul 2019
Herceptin	trastuzumab	Antibody	Anti-HER2	Breast cancer	Roche	6.8	Jul 2014/ Jun 2019
Neulasta	pegfilgrastim	Protein	G-CSF	Neutropenia	Amgen	4.4	Aug 2017/ Oct 2015

NHL = Non-Hodgkin’s lymphoma

The patents on almost all of these biological blockbusters will have expired by 2020, apart from Enbrel (etanercept) where the US patent has been extended to 2028 [3]. Considering just these eight biologicals, this will open up around US$63 billion in sales to competition from biosimilars. The biosimilars market earned revenue of approximately US$172 million in 2010 and with global sales of biologicals on the rise, this can only increase.

Related articles

US approvals of biologicals doubled in last decade

2012’s biggest patent expiries

References

1. GaBI Online - Generics and Biosimilars Initiative. Biologicals sales have almost doubled since 2006 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 6]. Available from: www.gabionline.net/Biosimilars/General/Biologicals-sales-have-almost-doubled-since-2006

2. GaBI Online - Generics and Biosimilars Initiative. US$67 billion worth of biosimilar patents expiring before 2020 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 6]. Available from: www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020

3. GaBI Online - Generics and Biosimilars Initiative. New Amgen Enbrel patent could block biosimilars until 2028 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 6]. Available from: www.gabionline.net/Biosimilars/News/New-Amgen-Enbrel-patent-could-block-biosimilars-until-2028

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Genetic Engineering News